A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin.

CONCLUSIONS: In this real-world study, patients with T2DM initiated on canagliflozin 300 mg had better HbA1c goal attainment and larger HbA1c reduction than patients initiated on dapagliflozin 10 mg. PMID: 29595326 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research